NVO

Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B · BCBA:NVO

9,500.00 ARS260.00 +2.81%

Novo Nordisk A/S ADR Cert Deposito Arg Repr 0.142857 ADR-B (BCBA:NVO) last traded at 9,500.00 ARS, up 2.81% on the day. Over the past year the stock is down 0.42%. Its 52-week range is 8,480.00 to 11,920.00. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open9,345.00

Day range9,345.00 – 9,505.00

52-week range8,480.00 – 11,920.00

Volume16.30 K

Average volume (10 days)11.57 K

Market cap (USD)175.64 B

P/E1.60

EPS (TTM) (USD)3.99

Dividend yield4.40%

Beta (1 year)0.1013

Revenue (TTM) (USD)50.21 B

Employees68.79 K

Performance

+2.81%1 week

+7.53%1 month

−11.21%3 months

−0.42%6 months

−0.42%Year to date

−0.42%1 year

Technical rating

Buy

Daily summary of 11 oscillators and 15 moving averages. See every indicator

Latest headlines

Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026

Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.